Welcome to mRNA Access
Leveraging the Power of mRNA for Global Health
At Moderna, we are grounded in the belief that mRNA is transformational. And, for us, our COVID-19 vaccine Spikevax® is just the beginning.
Our mRNA platform, with its speed, scale, and flexibility, is uniquely suited to tackle current and emerging pathogens that threaten global health.
mRNA Access, powered by Moderna, invites you to be part of what comes next.
What’s New
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
ESG DAY 2023
CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission
What we provide
mRNA Access Partnership Benefits
mRNA Access invites you to partner with us to explore the possibility of mRNA for the benefit of global health.
Moderna has spent a decade developing our mRNA platform to advance mRNA medicines. Our iterative vaccine design approach to emerging infectious disease like SARS-CoV-1 and MERS enabled our COVID-19 vaccine and allowed us to realize the potential of our platform to positively impact the lives of hundreds of millions of people.
Through mRNA Access, we invite researchers around the world to design novel vaccines against emerging and neglected infectious diseases, and, with the support of Moderna, leverage our platform to advance vaccines through pre-clinical development.
Researchers who join the collaborative model will have access to our platform and support from our research teams.
